New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 25, 2013
17:20 EDTGILD, MSFormer Morgan Stanley adviser charged in insider case, Bloomberg says
Former Morgan Stanley (MS) broker Kevin Dowd has been charged with insider trading related to Gilead's (GILD) $11B acquisition of Pharmasset in 2011, according to a Bloomberg report. Reference Link
News For MS;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 23, 2015
12:45 EDTGILDGilead July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
July 21, 2015
14:12 EDTGILDGilead reports study of E/C/F/TAF met primary endpoint
Gilead Sciences announced detailed 48-week data from an open-label Phase 3 study evaluating its investigational once-daily single tablet regimen of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg, or E/C/F/TAF, among 1,436 virologically suppressed adult patients switching from tenofovir disoproxil fumarate-containing regimens. The study met its primary endpoint by demonstrating non-inferiority of E/C/F/TAF to the TDF-based regimens at Week 48. The study also demonstrated statistical superiority among patients with HIV-1 RNA levels less than 50 copies/mL at Week 48 and statistically significant improvements in bone and renal laboratory parameters. These data were presented in an oral session at the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention in Vancouver, Canada. Among the 1,436 patients who were randomized in the study, virologic success rates at Week 48 were higher in patients taking E/C/F/TAF, 97% versus 93% for all TDF-based regimens; difference in percentages: 4.1%, 95% CI: 1.6% to 6.7%. The rates of virologic failure were similar between the two arms, with E/C/F/TAF, 1.0% and TDF-based regimen, 1.3%. General safety was similar between the two arms through 48 weeks of treatment, with similar percentages of patients in each group having any adverse events. Adverse events leading to treatment discontinuation were more common among patients treated with a TDF-based regimen.
08:49 EDTMSMorgan Stanley price target raised to $46 from $40 at BMO Capital
BMO Capital raised its price target on Morgan Stanley after the company reported higher than expected core Q2 EPS. The firm says that all of the company's segments delivered results that beat expectations. The firm raised its annual EPS estimates for the company by 2% and keeps an Outperform rating on the shares.
06:07 EDTMSONUG: Yahoo hires VP of global network from Symantec
Subscribe for More Information
July 20, 2015
13:03 EDTMSFed proposes final rule on capital surcharges for largest U.S. banks
Subscribe for More Information
12:08 EDTMSOn The Fly: Top stock stories at midday
Stocks on Wall Street were slightly higher at midday in the first trading day of a week that will be light on domestic economic data but heavy on earnings reports. Investors will be receiving profit reports from about 25% of the companies on the S&P 500 this week, making this the highest volume earnings week of this season. ECONOMIC EVENTS: In the U.S., no major data was released. In Europe, Greece reopened its banks three weeks after closing as the country worked out another bailout agreement. The country announced it has started the process of paying off its creditors, including the European Central Bank and the International Monetary Fund, with a bridge loan it just received. COMPANY NEWS: Lockheed Martin (LMT) agreed to buy the Sikorsky Aircraft business from United Technologies (UTX) for $9B, noting the price is "effectively reduced" to $7.1B after taking into account tax benefits resulting from the transaction. Shares of Lockheed, which also reported better than expected second quarter results and increased its fiscal year guidance, gained nearly 2% after the Sikorsky announcement and saying it will conduct a strategic review of its government IT infrastructure services business and technical services business... Shares of Morgan Stanley (MS) shares were little changed near noon after the bank reported earnings and revenue, excluding certain adjustments, that topped analysts' consensus forecasts... SunEdison (SUNE) announced a deal to acquire Vivint Solar (VSLR) for approximately $2.2B, payable in a combination of cash, shares of SunEdison common stock and SunEdison convertible notes. In connection with the proposed acquisition of Vivint Solar, SunEdison has entered into a definitive purchase agreement with a subsidiary of TerraForm Power (TERP) which, concurrently with the completion of SunEdison's acquisition of Vivint, will acquire Vivint Solar's rooftop solar portfolio, consisting of 523 MW expected to be installed by year-end 2015, for $922M in cash. Shares of Vivint rose 44% following the announcement, while SunEdison's stock gained 4% and TerraForm dropped 3%. Fellow residential solar installer SolarCity (SCTY), which is backed by Tesla's (TSLA) Elon Musk, rose 7% following the deal in the space. MAJOR MOVERS: Among the notable gainers was Exelixis (EXEL), which rallied 43% after the company reported that a study of cabozantinib in metastatic renal cell carcinoma met its primary endpoint of significant improvement in progression-free survival. The shares were indicated to rise even more in early pre-market trading, but lost some of their gains after Bristol-Myers (BMY) announced that its Opdivo study was stopped early after showing superior overall survival in a Phase 3 study of previously treated patients with advanced or metastatic renal cell carcinoma. Bristol-Myers rose a bit less than 1% to trade near $70 per share after its own announcement. Also higher was PayPal (PYPL), which gained more than 5.5% in its first day of trading after being spun out of eBay (EBAY). Meanwhile, eBay shares rose over 2%. Cal-Maine Foods (CALM) dropped 8% after posting lower than expected sales and profits in its fourth quarter and warning that while it should have an adequate supply of its primary feed ingredients, the company expects that prices will be "volatile" in the year ahead. Also lower were shares of several gold miners, including Barrick Gold (ABX) and Newmont Mining (NEM), which each fell about 11%, as gold prices declined about 2% near midday. INDEXES: Near midday, the Dow was up 31.66, or 0.18%, to 18,118.11, the Nasdaq was up 9.81, or 0.19%, to 5,219.96, and the S&P 500 was up 2.82, or 0.13%, to 2,129.46.
09:22 EDTMSOn The Fly: Pre-market Movers
Subscribe for More Information
08:47 EDTMSMorgan Stanley CFO: Retail investor activity yet to increase from subdued levels
Morgan Stanley CFO Jonathan Pruzan said the firm's view on Wealth Management remains positive as the recovery plays out in the U.S., with growth expected to come from its bank strategy and fee-based program. "We continue to see softness in transactional revenues, which were down 8% compared to last quarter as retail investor activity has yet to increase from subdued levels," Pruzan added.
08:43 EDTMSMorgan Stanley CEO says firm should benefit from being overweight U.S.
Subscribe for More Information
07:33 EDTGILDInternational AIDS Society to hold a conference
Subscribe for More Information
07:10 EDTMSMorgan Stanley rises 3.8% to $41.75 in pre-market after Q2 earnings beat
Subscribe for More Information
07:05 EDTMSMorgan Stanley reports tangible book value per common share $29.54
Subscribe for More Information
07:04 EDTMSMorgan Stanley reports Q2 Wealth Management net revenues $3.9B
Subscribe for More Information
07:01 EDTMSMorgan Stanley reports Q2 EPS ex DVA 79c, consensus 74c
Subscribe for More Information
July 19, 2015
19:12 EDTMSFederal Reserve proposes changes to 'stress test' regulations
Subscribe for More Information
July 17, 2015
15:20 EDTMSMorgan Stanley July weekly 40 straddle priced for 3.1% movement into Q2
14:00 EDTMSEarnings Watch: Morgan Stanley rounds out quarterly results for financial firms
Subscribe for More Information
13:34 EDTMSMorgan Stanley technical comments ahead of results
Subscribe for More Information
10:21 EDTGILDCigna says 98.4% of customers treated with hep C drug Harvoni are cured
Subscribe for More Information
09:03 EDTGILDGilead granted orphan status for gastric cancer treatment
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use